- Data Suggest Montelukast May Inhibit Mental Decline, Higher Doses Optimal for Clinical Trials Assessing Impact on Neurological Disease -

SAINT LAURENT, Quebec, Nov. 09, 2020 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that the peer-reviewed journal, International Journal of Clinical Pharmacy, has published a study on Montelukast’s effect on neurological aging.

“This study builds on a similar study conducted in 2017 that suggested that Montelukast could alleviate the cognitive decline associated with human aging,” said Dr. Ludwig Aigner, a member of IntelGenx’s Scientific Advisory Board. “We are very encouraged that the current study, which includes additional prescription database data and results from the Tromsø Study, further supports Montelukast’s potential to postpone mental aging.”

IntelGenx is currently conducting a Phase 2a clinical study of Montelukast VersaFilm® for the treatment of Alzheimer’s disease (“AD”).

The article, co-authored by Dr. Aigner from the Paracelsus Medical University in Salzburg, Austria, is entitled, “A possible effect of montelukast on neurological aging examined by the use of register data.” The article presents an observational study investigating if Montelukast may alleviate degenerative neurological changes, based on data from the Norwegian Prescription Database and the Tromsø Study, which sought to determine the reasons for the high mortality of various diseases, including neurological disease.

The study used multivariate linear regression analyses to see how the use of various medications was associated with neurological health test results. The study found that previous use of Montelukast correlated with improved scores on cognitive or neurological functioning, suggesting that Montelukast may alleviate degenerative neurological changes associated with human aging.

In addition, the study argues that the Montelukast dosage used for asthma may not be optimal for possible effects on the brain, suggesting a higher dose of Montelukast be used in clinical trials assessing Montelukast’s effect on cognitive decline.

Dr. Horst G. Zerbe, IntelGenx’s CEO, added, “The findings of this study are in agreement with the design of our Phase 2a trial of Montelukast VersaFilm, which is currently enrolling AD patients under an amended protocol using higher doses of Montelukast.”

The article may be accessed at: https://doi.org/10.1007/s11096-020-01160-8.

About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm® and VetaFilm™, as well as VevaDermTM, its transdermal development and manufacturing capabilities, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQB has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source: IntelGenx Technologies Corp.

For IntelGenx:

Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
This email address is being protected from spambots. You need JavaScript enabled to view it.


Andre Godin, CPA, CA
President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
This email address is being protected from spambots. You need JavaScript enabled to view it.